Rising incidence of diabetes, heart conditions and cancer are underpinning the physician-based POC diagnostic sector’s rapid growth
The market for POC diagnostic products used in the physician’s surgery was worth approximately US$4.1 billion in 2011 with sectors such as cholesterol testing and tumour markers making the best continued growth in the year. All sectors will see sustained growth over the medium term with the market forging ahead to be valued at over US$6 billion by 2017.
In the physician's office, POC diagnostics can play a key role in the diagnosis and ongoing monitoring of acute and chronic illnesses, the detection of some types of cancer, the monitoring of patients on anticoagulation drugs, and for general blood and urine testing. It can also play an important role in enabling preventative medicine, which is intended to help curb the increasing incidence of chronic conditions such as diabetes and cardiovascular disease through early detection and identifying patients with risk factors that mean they are likely to develop such conditions in the future.
There are several key challenges in the market. Currently, many physicians’ offices do not have budgets for in-house diagnostic testing and healthcare funding needs to change in order to provide incentives for doctors to use the products. For this to happen, healthcare providers need evidence that POC diagnostics provide benefits in terms of clinical-usefulness, convenience and cost.
This volume provides...
- Market growth forecasts by sector to 2017
- Over 100 companies listed with 14 detailed profiles
- Detailed operating environment analysis
All major testing technologies are covered
- Haemoglobin (HbA1c)
- Tumour marking
- C-reactive protein (CRP)
- Haematology & clinical chemistry SHOW LESS READ MORE >
About the Author
This report has been researched and written by independent medical market analyst Joanne Maddox. For over 13 years she has played a pivotal role in tracking trends in medical device and equipment markets and companies. A former editor of Medical Device Companies Analysis she has also written The Global Advanced Wound Care Market to 2017; Advances in Molecular Imaging 2013; and, Telemonitoring: Challenges and Opportunities.